Abstract: Belzutifan (PT2977 or MK-6482) is a first-in-class, orally active small-molecule inhibitor of hypoxia-inducible factor-2 alpha (HIF-2α). It has revolutionized the therapeutic landscape for clear cell renal cell carcinoma (ccRCC) and von Hippel-Lindau (VHL) disease-associated tumors. This comprehensive literature review synthesizes current research on belzutifan, focusing on its pharmacological activity, molecular mechanism of action, and structure-activity relationships. While belzutifan monotherapy has demonstrated significant clinical efficacy and gained regulatory approvals, its long-term utility is challenged by on-target adverse events—most notably anemia and hypoxia—as well as the emergence of acquired resistance mutations. Consequently, the research paradigm has rapidly shifted towards advanced solid tumor combination therapies. Ongoing clinical trials are rigorously evaluating belzutifan in combination with tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and CDK4/6 inhibitors to enhance anti-tumor synergy, overcome resistance mechanisms, and improve patient survival outcomes.
1. Introduction
The treatment landscape for advanced solid tumors, particularly metastatic clear cell renal cell carcinoma (ccRCC), has evolved significantly over the past two decades. Historically, the discovery of various pathways involved in renal cell carcinoma led to the development of biologically-driven targeted therapies, including vascular endothelial growth factor (VEGF) inhibitors, mechanistic target of rapamycin (mTOR) inhibitors, and immunotherapeutic agents [8]. However, despite these advancements, the 5-year survival rate for metastatic ccRCC remains low, necessitating the development of novel therapeutic strategies [5].
A central hallmark of ccRCC and hereditary von Hippel-Lindau (VHL) disease is the inactivation of the VHL tumor suppressor gene, which occurs in approximately 90% of ccRCC tumors [1]. This inactivation leads to the constitutive activation of hypoxia-inducible factor-2 alpha (HIF-2α), driving a pseudohypoxic response that promotes angiogenesis and tumor growth [2]. Belzutifan (PT2977/MK-6482) was developed as a highly specific HIF-2α inhibitor to directly target this underlying pathogenesis. It received its first US Food and Drug Administration (FDA) approval in 2021 for VHL disease-associated tumors, followed by approval in 2023 for sporadic advanced ccRCC previously treated with immune checkpoint inhibitors and anti-angiogenic therapies [1] [4]. In 2025, the European Medicines Agency (EMA) also granted approval for belzutifan for certain VHL disease-associated tumors [9]. Current research is now heavily focused on integrating belzutifan into combination regimens to maximize its efficacy in advanced solid tumors.
2. Pharmacological Activity
Belzutifan exhibits a favorable pharmacokinetic profile characterized by a linear two-compartment model with first-order absorption and elimination. It has a half-life of approximately 14 hours and reaches steady-state concentration after about 3 days [3]. The drug is primarily metabolized by UGT2B17 and CYP2C19, and no dose adjustments are required based on age, sex, race, or mild-to-moderate renal/hepatic impairment [3].
Clinically, belzutifan has demonstrated robust anti-tumor activity. In the pivotal phase II LITESPARK-004 trial for VHL disease, belzutifan achieved an objective response rate (ORR) of 49% in RCC tumors, 77% in pancreatic lesions, and 30% in central nervous system (CNS) hemangioblastomas [3] [4]. For sporadic advanced ccRCC, the phase III LITESPARK-005 trial demonstrated that belzutifan significantly improved progression-free survival (PFS) and ORR (21.9% vs. 3.5%) compared to everolimus in heavily pretreated patients [3] [4]. A recent meta-analysis of belzutifan in advanced ccRCC reported a pooled ORR of 34% and a disease control rate (DCR) of 79%, with a median duration of response of 21.8 months [6].
In the context of combination therapy, belzutifan has shown synergistic potential. The phase II LITESPARK-003 trial evaluating belzutifan plus the TKI cabozantinib reported an impressive ORR of 70% in treatment-naive patients and 31% in previously treated patients [4] [6]. Similarly, the KEYMAKER-U03B study investigating belzutifan combined with lenvatinib showed an ORR of 50% in patients who had progressed on prior immunotherapy and VEGF-TKIs [3] [5].
3. Molecular Mechanism of Action
Under normoxic conditions, oxygen-dependent prolyl hydroxylases (PHDs) hydroxylate specific proline residues on HIF-2α. This hydroxylation creates a recognition site for the VHL protein (pVHL) E3 ubiquitin ligase complex, which targets HIF-2α for rapid proteasomal degradation [1]. In hypoxic environments, or when the VHL gene is mutated or deleted (as seen in ccRCC), HIF-2α is not degraded. It accumulates and translocates to the nucleus, where it heterodimerizes with the aryl hydrocarbon receptor nuclear translocator (ARNT), also known as HIF-1β [1] [3].
The HIF-2α/HIF-1β complex acts as a potent transcription factor that binds to hypoxia-response elements (HREs) in the DNA, driving the expression of over 100 genes involved in tumor survival, including VEGF (promoting angiogenesis), erythropoietin (EPO), and Cyclin D1 (CCND1, promoting cell cycle progression) [1] [5]. Belzutifan functions as an allosteric inhibitor that specifically binds to HIF-2α, inducing a conformational change that prevents its dimerization with HIF-1β. By disrupting this critical protein-protein interaction, belzutifan effectively halts the downstream transcription of oncogenic and angiogenic factors, thereby inhibiting tumor growth and progression [3] [4].
4. Structure-Activity Relationship (SAR)
For a long time, HIF-2α was considered an "undruggable" target due to the lack of traditional deep binding pockets. However, structural biology efforts identified a large, enclosed lipophilic cavity within the PAS-B domain of HIF-2α that is amenable to small-molecule ligand binding [1] [3]. First-generation inhibitors, such as PT2385 and PT2399, were developed to bind this cavity and allosterically block dimerization [1] [7]. While PT2385 showed proof-of-concept clinical activity, it was limited by suboptimal pharmacokinetics and variable exposure [1] [3].
Belzutifan (PT2977) was subsequently developed as a second-generation inhibitor. Structural modifications improved its potency, selectivity, and pharmacokinetic consistency compared to PT2385 [3] [4]. Belzutifan binds tightly to the PAS-B pocket, with allosteric effects mainly mediated by key residues such as M252 near the dimer interface, effectively destabilizing the HIF-2α/ARNT complex [4]. The precise structural fit of belzutifan is critical for its activity; alterations in the binding pocket directly impact drug efficacy, which forms the basis for acquired resistance mechanisms.
5. Current Limitations
Despite its clinical success, belzutifan therapy is associated with specific limitations, primarily related to on-target toxicities and the development of drug resistance.
Adverse Events: Because HIF-2α plays a role in normal physiology, its systemic inhibition leads to distinct side effects. Anemia is the most common adverse event, occurring in over 80% of patients, driven by the suppression of HIF-2α-mediated erythropoietin (EPO) production [3] [6] [9]. Hypoxia is another significant and unique toxicity, observed in approximately 16% of patients, which can lead to dose reductions, treatment discontinuation, or the need for supplemental oxygen [1] [9]. The mechanism of hypoxia is multifactorial, likely involving both anemia-induced reduced oxygen-carrying capacity and the direct inhibition of HIF-2α in the carotid body, which blunts the normal hypoxic ventilatory response [1].
Resistance Mechanisms: Acquired resistance to belzutifan eventually occurs in most patients. Structural and molecular analyses have identified "gatekeeper" mutations, most notably the G323E substitution in the EPAS1 gene (which encodes HIF-2α). This mutation alters the PAS-B binding pocket, sterically hindering belzutifan from binding [3] [5]. Additionally, an F446L mutation in HIF-1β has been identified, which enhances its binding affinity for HIF-2α, effectively outcompeting the inhibitor [3]. Other proposed resistance pathways include the elevation of phosphoglycerate dehydrogenase (PHGDH) in HIF-2α negative cells and the upregulation of FK506 binding protein 10 (FKB10) [3].
6. Future Perspectives
To overcome resistance and improve survival, the future of belzutifan lies in rational combination therapies and the development of next-generation inhibitors.
Combination Therapies: Multiple phase III trials are currently investigating belzutifan in combination with other targeted agents. The LITESPARK-011 trial is evaluating belzutifan plus the TKI lenvatinib versus cabozantinib in previously treated ccRCC [4] [5]. In the first-line setting, triplet therapies are being explored, such as belzutifan combined with lenvatinib and the ICI pembrolizumab (LITESPARK-012) [2] [5]. Furthermore, because HIF-2α upregulates Cyclin D1, there is a strong rationale for combining belzutifan with CDK4/6 inhibitors. The LITESPARK-024 trial is currently assessing belzutifan plus palbociclib [3] [4]. Other novel combinations include pairing belzutifan with HC-7366 (a GCN2 kinase activator) and anti-TIGIT therapies (vibostolimab) [2] [3].
Next-Generation Inhibitors: To address gatekeeper mutations like G323E, newer generation HIF-2α inhibitors are entering early-phase clinical trials. Agents such as NKT2152, DFF332, and BPI-452080 are currently being evaluated for safety and preliminary efficacy in advanced solid tumors [4] [5]. Future research will also need to focus on identifying predictive biomarkers (e.g., HIF-2α expression levels via PET imaging) to better select patients who will derive the most benefit from HIF-targeted therapies [3].
